000120385 001__ 120385
000120385 005__ 20240228135019.0
000120385 0247_ $$2doi$$a10.3748/wjg.v20.i35.12367
000120385 0247_ $$2pmid$$apmid:25253937
000120385 0247_ $$2pmc$$apmc:PMC4168070
000120385 0247_ $$2ISSN$$a1007-9327
000120385 0247_ $$2ISSN$$a2219-2840
000120385 0247_ $$2altmetric$$aaltmetric:2893221
000120385 037__ $$aDKFZ-2017-00818
000120385 041__ $$aeng
000120385 082__ $$a610
000120385 1001_ $$aHerzer, Kerstin$$b0
000120385 245__ $$aHepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.
000120385 260__ $$aBeijing$$bWJG Press$$c2014
000120385 3367_ $$2DRIVER$$aarticle
000120385 3367_ $$2DataCite$$aOutput Types/Journal article
000120385 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1495094067_1726$$xReview Article
000120385 3367_ $$2BibTeX$$aARTICLE
000120385 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120385 3367_ $$00$$2EndNote$$aJournal Article
000120385 520__ $$aSuccessful escape from immune response characterises chronic hepatitis C virus (HCV) infection, which results in persistence of infection in about 80% of the patients. The deleterious consequences are cirrhosis and hepatocellular carcinoma. HCV accounts the most frequent cause for hepatocellular carcinoma (HCC) and liver transplantation (LT) in the western world. The underlying molecular mechanisms how HCV promotes tumor development are largely unknown. There is some in vitro and in vivo evidence that HCV interferes with the tumor suppressor PML and may thereby importantly contribute to the HCV-associated pathogenesis with respect to the development of HCC. The tumor suppressor protein 'promyelocytic leukemia' (PML) has been implicated in the regulation of important cellular processes like differentiation and apoptosis. In cancer biology, PML and its associated nuclear bodies (NBs) have initially attracted intense interest due to its role in the pathogenesis of acute promyelocytic leukemia (APL). More recently, loss of PML has been implicated in human cancers of various histologic origins. Moreover, number and intensity of PML-NBs increase in response to interferons (IFNs) and there is evidence that PML-NBs may represent preferential targets in viral infections. Thus, PML could not only play a role in the mechanisms of the antiviral action of IFNs but may also be involved in a direct oncogenic effect of the HCV on hepatocytes. This review aims to summarise current knowledge about HCV-related liver carcinogenesis and to discuss a potential role of the nuclear body protein PML for this this hard-to-treat cancer.
000120385 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000120385 588__ $$aDataset connected to CrossRef, PubMed,
000120385 650_7 $$2NLM Chemicals$$aNuclear Proteins
000120385 650_7 $$2NLM Chemicals$$aPromyelocytic Leukemia Protein
000120385 650_7 $$2NLM Chemicals$$aTranscription Factors
000120385 650_7 $$2NLM Chemicals$$aTumor Suppressor Proteins
000120385 650_7 $$0143220-95-5$$2NLM Chemicals$$aPML protein, human
000120385 7001_ $$aGerken, Guido$$b1
000120385 7001_ $$0P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6$$aHofmann, Thomas$$b2$$eLast author$$udkfz
000120385 773__ $$0PERI:(DE-600)2084831-6$$a10.3748/wjg.v20.i35.12367$$gVol. 20, no. 35, p. 12367 -$$n35$$p12367 -$$tWorld journal of gastroenterology$$v20$$x1007-9327$$y2014
000120385 909CO $$ooai:inrepo02.dkfz.de:120385$$pVDB
000120385 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120385 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000120385 9141_ $$y2014
000120385 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000120385 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120385 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bWORLD J GASTROENTERO : 2015
000120385 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120385 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120385 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120385 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120385 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120385 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120385 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120385 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120385 9201_ $$0I:(DE-He78)A210-20160331$$kA210$$lZelluläre Seneszenz$$x0
000120385 980__ $$ajournal
000120385 980__ $$aVDB
000120385 980__ $$aI:(DE-He78)A210-20160331
000120385 980__ $$aUNRESTRICTED